Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology
…, M Muto, T Ito, K Furutsuka, T Yamasaki… - Journal of Nuclear …, 2014 - Soc Nuclear Med
2-((1E,3E)-4-(6-( 11 C-methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ( 11 C-PBB3)
is a clinically useful PET probe that we developed for in vivo imaging of tau pathology …
is a clinically useful PET probe that we developed for in vivo imaging of tau pathology …
[HTML][HTML] PET Imaging of Lung Inflammation with [18F]FEDAC, a Radioligand for Translocator Protein (18 kDa)
A Hatori, J Yui, T Yamasaki, L Xie, K Kumata… - 2012 - journals.plos.org
Purpose The translocator protein (18 kDa) (TSPO) is highly expressed on the bronchial and
bronchiole epithelium, submucosal glands in intrapulmonary bronchi, pneumocytes and …
bronchiole epithelium, submucosal glands in intrapulmonary bronchi, pneumocytes and …
[HTML][HTML] Synthesis and preclinical evaluation of sulfonamido-based [11C-carbonyl]-carbamates and ureas for imaging monoacylglycerol lipase
…, BH Rotstein, M Fujinaga, Y Shimoda, T Yamasaki… - Theranostics, 2016 - ncbi.nlm.nih.gov
Monoacylglycerol lipase (MAGL) is a 33 kDa member of the serine hydrolase superfamily
that preferentially degrades 2-arachidonoylglycerol (2-AG) to arachidonic acid in the …
that preferentially degrades 2-arachidonoylglycerol (2-AG) to arachidonic acid in the …
Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease
L Xie, J Yui, A Hatori, T Yamasaki, K Kumata… - Journal of …, 2012 - Elsevier
BACKGROUND & AIMS: Mitochondrial dysfunction is responsible for liver damage and disease
progression in non-alcoholic fatty liver disease (NAFLD). Translocator protein (18kDa) (…
progression in non-alcoholic fatty liver disease (NAFLD). Translocator protein (18kDa) (…
[HTML][HTML] [18F] FEBMP: positron emission tomography imaging of TSPO in a model of neuroinflammation in rats, and in vitro autoradiograms of the human brain
AK Tiwari, B Ji, J Yui, M Fujinaga, T Yamasaki, L Xie… - Theranostics, 2015 - ncbi.nlm.nih.gov
We evaluated the efficacy of 2-[5-(4-[18 F] fluoroethoxy-2-oxo-1, 3-benzoxazol-3 (2H)-yl)-N-methyl-N-phenylacetamide]([18
F] FEBMP) for positron emission tomography (PET) imaging …
F] FEBMP) for positron emission tomography (PET) imaging …
18F-FEAC and 18F-FEDAC: PET of the monkey brain and imaging of translocator protein (18 kDa) in the infarcted rat brain
…, K Yanamoto, A Hatori, T Yamasaki… - Journal of Nuclear …, 2010 - Soc Nuclear Med
We evaluated two 18 F-labeled PET ligands, N-benzyl-N-ethyl-2-[7,8-dihydro-7-(2- 18 F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide
( 18 F-FEAC) and N-benzyl-N-methyl-2-[7,8…
( 18 F-FEAC) and N-benzyl-N-methyl-2-[7,8…
αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4
…, M Degardin, A Sugyo, AB Tsuji, T Yamasaki… - Molecular Cancer …, 2016 - AACR
The transmembrane cell adhesion receptor α V β 3 integrin (α V β 3 ) has been identified as
an important molecular target for cancer imaging and therapy. We have developed a …
an important molecular target for cancer imaging and therapy. We have developed a …
[HTML][HTML] Utility of translocator protein (18 kDa) as a molecular imaging biomarker to monitor the progression of liver fibrosis
A Hatori, J Yui, L Xie, K Kumata, T Yamasaki… - Scientific reports, 2015 - nature.com
Hepatic fibrosis is the wound healing response to chronic hepatic injury caused by various
factors. In this study, we aimed to evaluate the utility of translocator protein (18 kDa) (TSPO) …
factors. In this study, we aimed to evaluate the utility of translocator protein (18 kDa) (TSPO) …
[11C]Gefitinib ([11C]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma
…, A Hatori, N Takai, J Toyohara, T Yamasaki… - Molecular imaging and …, 2010 - Springer
Objective Gefitinib (N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine,
Iressa) is an approved anticancer drug. In this study, we labeled gefitinib …
Iressa) is an approved anticancer drug. In this study, we labeled gefitinib …
In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [11C] gefitinib
K Kawamura, T Yamasaki, J Yui, A Hatori… - Nuclear medicine and …, 2009 - Elsevier
Gefitinib (Iressa) is a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine
kinase. Recent studies confirmed that gefitinib interacted with the breast cancer resistance …
kinase. Recent studies confirmed that gefitinib interacted with the breast cancer resistance …